Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage
To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.
A phase III prospective pragmatic double blind randomised placebo controlled trial
Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham
Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian
Dr Matt Reed is the local contact for recruitment of ED patients into the study.
Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.
For more information please refer to main trial website
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions